4//SEC Filing
Anthera Pharmaceuticals Inc 4
Accession 0001214659-15-007879
CIK 0001316175operating
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 6:53 PM ET
Size
9.7 KB
Accession
0001214659-15-007879
Insider Transaction Report
Form 4
Hislop Colin
Sr. VP, Cardiovasc. Prod.
Transactions
- Sale
Common Stock
2015-11-13$5.31/sh−12,500$66,341→ 19,147 total - Exercise/Conversion
Common Stock
2015-11-13$1.61/sh+12,500$20,125→ 31,647 total - Exercise/Conversion
Stock option
2014-12-30−12,500→ 107,500 totalExercise: $1.61Exp: 2024-12-30→ Common Stock (12,500 underlying)
Holdings
- 1,897(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2015.
- [F2]The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.
- [F3]This stock option vests monthly over four years beginning December 30, 2014 (the Vesting Start Date). The Stock Option is completely vested on the fourth anniversary of the vesting start and will expire on December 30, 2024
Documents
Issuer
Anthera Pharmaceuticals Inc
CIK 0001316175
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001316175
Filing Metadata
- Form type
- 4
- Filed
- Nov 17, 7:00 PM ET
- Accepted
- Nov 18, 6:53 PM ET
- Size
- 9.7 KB